PolyPid - רווח למניה אחת ב-12 החודשים האחרונים PYPD

PolyPid Ltd. develops targeted antibiotic delivery systems to protect patients post-surgery. The annual EPS TTM growth illustrates profit dynamics, where the value 54.50 represents the current figure. High crisis resilience and a lack of seasonality in surgery, combined with the potential to enter a monopoly niche following final tests, provide the company with significant competitive advantages.

High margins from royalties on patented gel capsules provide PolyPid Ltd. (PYPD) with exceptional financial stability. By analyzing the annual EPS growth rate over the last 12 months, an investor assesses net income per share dynamics by comparing the current rolling window with the same period last year, allowing for the timely identification of a slowdown in business value growth and the adjustment of the asset's fair value estimate.